Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Abdominal Pain

ClinicalTrials.gov lists 413 trials for Abdominal Pain or a narrower condition beneath it. Zagazig University has the most among industry and government lead sponsors, with 5.

MeSH D015746 Pathological Conditions, Signs and Symptoms C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 9 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 31 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 34 Phase 4 Phase 4 28 Not applicable Not applicable 183 Observational Observational 110 Phase 1 Phase 1 9 Phase 1/2 Phase 1/2 8 Phase 2 Phase 2 31 Phase 2/3 Phase 2/3 10 Phase 3 Phase 3 34 Phase 4 Phase 4 28 Not applicable Not applicable 183 Observational Observational 110

Trials per phase (log scale)

361 of the 413 trials are tagged with Abdominal Pain itself; the rest are tagged with a narrower condition beneath it.

Get the Abdominal Pain report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Abdominal Pain trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 28

1994: 1 trials (Phase 3 1) 1996: 1 trials (Phase 3 1) 1998: 2 trials (Not applicable 1, Phase 1/2 1) 1999: 1 trials (Not applicable 1) 2000: 1 trials (Phase 3 1) 2001: 4 trials (Observational 3, Not applicable 1) 2002: 2 trials (Not applicable 1, Phase 4 1) 2003: 2 trials (Phase 4 1, Phase 2 1) 2004: 9 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2/3 2, Phase 2 2, Phase 1 1) 2005: 8 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 2 1, Phase 1/2 1, Phase 1 1) 2006: 5 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1) 2007: 6 trials (Not applicable 2, Phase 3 2, Phase 2/3 1, Phase 2 1) 2008: 14 trials (Observational 4, Not applicable 4, Phase 4 2, Phase 3 3, Phase 1 1) 2009: 16 trials (Observational 4, Not applicable 5, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1 1) 2010: 16 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 3 2, Phase 2 4, Phase 1 1) 2011: 18 trials (Observational 1, Not applicable 9, Phase 4 1, Phase 3 3, Phase 2 2, Phase 1/2 1, Phase 1 1) 2012: 17 trials (Observational 3, Not applicable 7, Phase 4 1, Phase 3 2, Phase 2 4) 2013: 12 trials (Observational 1, Not applicable 6, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 1/2 1) 2014: 22 trials (Observational 6, Not applicable 9, Phase 4 3, Phase 3 2, Phase 2/3 1, Phase 2 1) 2015: 28 trials (Observational 9, Not applicable 13, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 1) 2016: 19 trials (Observational 6, Not applicable 8, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1) 2017: 28 trials (Observational 13, Not applicable 9, Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 2 1, Phase 1 1) 2018: 10 trials (Observational 8, Not applicable 1, Phase 4 1) 2019: 22 trials (Observational 8, Not applicable 12, Phase 2 2) 2020: 21 trials (Observational 10, Not applicable 6, Phase 4 2, Phase 3 1, Phase 2 1, Phase 1 1) 2021: 22 trials (Observational 2, Not applicable 12, Phase 4 5, Phase 3 1, Phase 2 2) 2022: 16 trials (Observational 7, Not applicable 8, Phase 3 1) 2023: 21 trials (Observational 3, Not applicable 17, Phase 3 1) 2024: 20 trials (Observational 7, Not applicable 11, Phase 3 2) 2025: 26 trials (Observational 5, Not applicable 16, Phase 2/3 1, Phase 2 2, Phase 1/2 2)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 21
2025 26
2024 20
2023 21
2022 16
2021 22
2020 21
2019 22
2018 10
2017 28

Forecast of the full-year count, planned starts included, not rows of this table: about 26 trials starting in 2026 and about 24 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 35 months from start to primary completion across 17 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 278 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Abdominal Pain trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 9
Phase 1/2 8
Phase 2 31
Phase 2/3 10
Phase 3 34
Phase 4 28
Not applicable 183
Observational 110

How many Abdominal Pain trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 23
Recruiting 30
Enrolling by invitation 2
Active, not recruiting 4
Completed 254

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Abdominal Pain trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Zagazig University 5
Abbott 4
Bausch Health Americas, Inc. 4
DiaSorin Inc. 3

Which drugs are being tested for Abdominal Pain? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
PMI-150 (intranasal ketamine) 3
Dronabinol 3

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
PO Morphine 8
Acupuncture 4
L:Lidocaine 4
Ondansetron - Parts A + B 4
Probiotics 2

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Abdominal Pain trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Severe desaturation: SpO2 < 85% 9 1
Apnea 6 1
CVS, Nausea 6 1
Colitis ulcerative 6 1
Pneumonia 6 3

Which publications cover Abdominal Pain? (1,015)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages